3M Drug Delivery to Manufacture Transdermal Patch in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3M Drug Delivery to Manufacture Transdermal Patch in Europe



The specialty pharmaceutical company ProStrakan Group has received approval from EMA to market Sancuso (granisetron transdermal system) in the European Union, with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan began marketing the product in October 2013 in the United Kingdom, Germany, and the Netherlands. Additional European countries are expected to be added in 2014.

Initially introduced in the United States in 2008, Sancuso is used to treat chemotherapy-induced nausea and vomiting. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting.

ProStrakan previously relied on a different manufacturer for the US supply of Sancuso. FDA approval is currently pending for the 3M Drug Delivery Systems manufactured product.

Source: 3M Drug Delivery Systems

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here